
|Articles|November 7, 2012
Dermatology drug developer raises $16M
Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
KT-621 in Atopic Dermatitis: What Early EASI and Pruritus Data Show
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
What Dermatologists Need to Know About the First New Sunscreen Ingredient in Decades
5














